Advertising

Becton Dickinson

BDX-N

NYSE:BDX

254.74
1.03 (0.40%)
Becton, Dickinson and Company is an American medical technology company that manufactures and sells medical devices, instrument systems, and reagents.
More at Wikipedia

Analysis and Opinions about BDX-N

Signal
Opinion
Expert
Chart
HOLD
HOLD
July 19, 2021
Big medical supplies. They also have some proprietary parts of the business. He sold it about a month ago to buy one of today's top picks. You won't do too badly owning this going forward.
Show full opinionHide full opinion
Big medical supplies. They also have some proprietary parts of the business. He sold it about a month ago to buy one of today's top picks. You won't do too badly owning this going forward.
Barry Schwartz
Price
$247.250
Owned
No
PAST TOP PICK
PAST TOP PICK
May 27, 2021
(A Top Pick Apr 21/20, Down 4%) Hurt during Covid by surgeries not being performed. Should have a strong 2021.
Show full opinionHide full opinion
(A Top Pick Apr 21/20, Down 4%) Hurt during Covid by surgeries not being performed. Should have a strong 2021.
Lorne Steinberg
Price
$241.700
Owned
Yes
HOLD
HOLD
March 29, 2021
He has no plans to sell it. They were very strong last year. It has been a little slow this year. You are not going to have explosive growth every single year. You might want to watch it and buy it if it dips coming out of the pandemic.
Show full opinionHide full opinion
He has no plans to sell it. They were very strong last year. It has been a little slow this year. You are not going to have explosive growth every single year. You might want to watch it and buy it if it dips coming out of the pandemic.
WAIT
WAIT
February 11, 2021
Syringes, IVs, disposable items. On his hot watch list. He's looking at hospital utilization rates. The market is waiting too. Once rates tick up, they'll be a direct beneficiary.
Show full opinionHide full opinion
Becton Dickinson (BDX-N)
February 11, 2021
Syringes, IVs, disposable items. On his hot watch list. He's looking at hospital utilization rates. The market is waiting too. Once rates tick up, they'll be a direct beneficiary.
Paul MacDonald
Price
$251.980
Owned
No
WATCH
WATCH
January 22, 2021
90% of the things they make are disposables. They make syringes among other things. The products are diversified and one does not dominate their revenues. There are many operations that should have happened but have not due to covid. Earnings will accelerate once covid has subsided and procedures restart.
Show full opinionHide full opinion
Becton Dickinson (BDX-N)
January 22, 2021
90% of the things they make are disposables. They make syringes among other things. The products are diversified and one does not dominate their revenues. There are many operations that should have happened but have not due to covid. Earnings will accelerate once covid has subsided and procedures restart.
Lorne Steinberg
Price
$260.490
Owned
Unknown
WATCH
WATCH
January 22, 2021
90% of the things they make are disposables. They make syringes among other things. The products are diversified and one does not dominate their revenues. There are many operations that should have happened but have not due to covid. Earnings will accelerate once covid has subsided and procedures restart.
Show full opinionHide full opinion
Becton Dickinson (BDX-N)
January 22, 2021
90% of the things they make are disposables. They make syringes among other things. The products are diversified and one does not dominate their revenues. There are many operations that should have happened but have not due to covid. Earnings will accelerate once covid has subsided and procedures restart.
Lorne Steinberg
Price
$260.490
Owned
Unknown
TOP PICK
TOP PICK
December 10, 2020

"Canadian Tire" of healthcare products for clinics and medical offices. Products are one-use only. Elective surgeries have been cancelled, so stock has not done much. Will shine in post-Covid era. Yield is 1.38%. (Analysts’ price target is $272.31)

Show full opinionHide full opinion
Becton Dickinson (BDX-N)
December 10, 2020

"Canadian Tire" of healthcare products for clinics and medical offices. Products are one-use only. Elective surgeries have been cancelled, so stock has not done much. Will shine in post-Covid era. Yield is 1.38%. (Analysts’ price target is $272.31)

David Baskin
Price
$242.340
Owned
Yes
BUY
BUY
October 26, 2020

Healthcare gets knocked down before an election so there is a constant battle at this time of year and then it disappears after the election. This is a great company and continues to do well and you should own it or SYK-N, which he owns.

Show full opinionHide full opinion
Becton Dickinson (BDX-N)
October 26, 2020

Healthcare gets knocked down before an election so there is a constant battle at this time of year and then it disappears after the election. This is a great company and continues to do well and you should own it or SYK-N, which he owns.

Paul Harris, CFA
Price
$242.335
Owned
No
DON'T BUY
DON'T BUY
October 7, 2020

BDX vs. BSX Owns Boston Scientific instead, with a strong history of execution. One-time events threw off that execution. Hospital procedures are coming back, which will benefit the entire industry. BSX is better known for innovation.

Show full opinionHide full opinion
Becton Dickinson (BDX-N)
October 7, 2020

BDX vs. BSX Owns Boston Scientific instead, with a strong history of execution. One-time events threw off that execution. Hospital procedures are coming back, which will benefit the entire industry. BSX is better known for innovation.

Jennifer Radman
Price
$237.300
Owned
No
BUY
BUY
October 2, 2020
A medical products company. They had a recall of one of their products this year, and they were late on the ball with covid testing. Now that things are open again and people are going to the hospital, they should have a positive outlook.
Show full opinionHide full opinion
Becton Dickinson (BDX-N)
October 2, 2020
A medical products company. They had a recall of one of their products this year, and they were late on the ball with covid testing. Now that things are open again and people are going to the hospital, they should have a positive outlook.
Barry Schwartz
Price
$232.660
Owned
Unknown
BUY
BUY
September 30, 2020
A good opportunity. Covid has led to deferral of elective surgeries, so revenues are suffering and the market didn't like this. Vaccine testing will help them quite a bit to monetize their testing technology. Reasonable opportunity. Wouldn't be shy to buy at these levels.
Show full opinionHide full opinion
Becton Dickinson (BDX-N)
September 30, 2020
A good opportunity. Covid has led to deferral of elective surgeries, so revenues are suffering and the market didn't like this. Vaccine testing will help them quite a bit to monetize their testing technology. Reasonable opportunity. Wouldn't be shy to buy at these levels.
Gordon Reid
Price
$233.885
Owned
Unknown
BUY
BUY
August 25, 2020
Allan Tong’s Discover Picks The pandemic helped BDX, since most of its products are disposable. Then again, during the spring lockdown, surgeries were cancelled across the board, so use of BDX's products nearly halted. Its chart this year has been rocky, though earlier this month, the stock returned to previous highs above $280 while it has met or narrowly beat its EPS in the past four quarters. BDX continues to be profitable at a margin of 7.13% and a 15.41% five-year average revenue growth. Forward PE stands at 20.44x and it pays a dividend of 1.2%. Read BDX, BSX, ISRG and Stryker Stock: Top 4 Medical Supply Stocks for our full analysis.
Show full opinionHide full opinion
Becton Dickinson (BDX-N)
August 25, 2020
Allan Tong’s Discover Picks The pandemic helped BDX, since most of its products are disposable. Then again, during the spring lockdown, surgeries were cancelled across the board, so use of BDX's products nearly halted. Its chart this year has been rocky, though earlier this month, the stock returned to previous highs above $280 while it has met or narrowly beat its EPS in the past four quarters. BDX continues to be profitable at a margin of 7.13% and a 15.41% five-year average revenue growth. Forward PE stands at 20.44x and it pays a dividend of 1.2%. Read BDX, BSX, ISRG and Stryker Stock: Top 4 Medical Supply Stocks for our full analysis.
BUY
BUY
August 24, 2020
One of the better US healthcare companies, making needles and test tubes. BDX has done very well in recent years though flat during COVID, so he expects a catch-up. No reason to be afraid of this. It's a solid stock that will grow 3-5% annually.
Show full opinionHide full opinion
Becton Dickinson (BDX-N)
August 24, 2020
One of the better US healthcare companies, making needles and test tubes. BDX has done very well in recent years though flat during COVID, so he expects a catch-up. No reason to be afraid of this. It's a solid stock that will grow 3-5% annually.
Bruce Murray
Price
$254.775
Owned
Unknown
PAST TOP PICK
PAST TOP PICK
July 31, 2020
(A Top Pick Jun 24/19, Up 12%) The only company that can manufacture disposable, consumable medical products, especially syringes. They benefit from the pandemic and will benefit from the aging population.
Show full opinionHide full opinion
(A Top Pick Jun 24/19, Up 12%) The only company that can manufacture disposable, consumable medical products, especially syringes. They benefit from the pandemic and will benefit from the aging population.
Barry Schwartz
Price
$281.340
Owned
Yes
PAST TOP PICK
PAST TOP PICK
June 15, 2020
(A Top Pick Jun 24/19, Down 6%) Hospitals were kind of closed across North America. These guys were a supplier for hospitals. If there are no surgeries then there is less demand for their one time use products. A billion plus doses of a vaccine will require their syringes.
Show full opinionHide full opinion
(A Top Pick Jun 24/19, Down 6%) Hospitals were kind of closed across North America. These guys were a supplier for hospitals. If there are no surgeries then there is less demand for their one time use products. A billion plus doses of a vaccine will require their syringes.
Barry Schwartz
Price
$235.695
Owned
Yes
Showing 1 to 15 of 78 entries

Becton Dickinson(BDX-N) Rating

Ranking : 4 out of 5

Bullish - Buy Signals / Votes : 6

Neutral - Hold Signals / Votes : 2

Bearish - Sell Signals / Votes : 1

Total Signals / Votes : 9

Stockchase rating for Becton Dickinson is calculated according to the stock experts' signals. A high score means experts mostly recommend to buy the stock while a low score means experts mostly recommend to sell the stock.

Becton Dickinson(BDX-N) Frequently Asked Questions

What is Becton Dickinson stock symbol?

Becton Dickinson is a American stock, trading under the symbol BDX-N on the New York Stock Exchange (BDX). It is usually referred to as NYSE:BDX or BDX-N

Is Becton Dickinson a buy or a sell?

In the last year, 9 stock analysts published opinions about BDX-N. 6 analysts recommended to BUY the stock. 1 analyst recommended to SELL the stock. The latest stock analyst recommendation is HOLD. Read the latest stock experts' ratings for Becton Dickinson.

Is Becton Dickinson a good investment or a top pick?

Becton Dickinson was recommended as a Top Pick by Barry Schwartz on 2021-07-19. Read the latest stock experts ratings for Becton Dickinson.

Why is Becton Dickinson stock dropping?

Earnings reports or recent company news can cause the stock price to drop. Read stock experts’ recommendations for help on deciding if you should buy, sell or hold the stock.

Is Becton Dickinson worth watching?

9 stock analysts on Stockchase covered Becton Dickinson In the last year. It is a trending stock that is worth watching.

What is Becton Dickinson stock price?

On 2021-08-04, Becton Dickinson (BDX-N) stock closed at a price of $254.74.